Biohaven's FGFR3-Directed ADC BHV-1530 Wins Oral ENA 2026 Slot as Cemiplimab Combination Begins Enrolling
核心洞察
Biohaven's Phase 1 data on BHV-1530, a first-in-class FGFR3 (搜索)-directed antibody-drug conjugate, have been accepted for an oral presentation at the EORTC-NCI-AACR Symposium in Barcelona, November 18-20, 2026.
The ongoing BHV1530-101 study has shown confirmed partial responses in heavily pretreated patients with no dose-limiting toxicities and no FGFR inhibitor-class toxicities such as hyperphosphatemia, nail disorders, stomatitis or retinopathy.
Under a clinical supply agreement with Regeneron, Biohaven has begun enrolling a cohort testing BHV-1530 with cemiplimab (Libtayo) based on preclinical evidence of synergy with anti-PD-1 therapy.
Biohaven Ltd. (搜索) said data from its Phase 1 program for BHV-1530, an FGFR3 (搜索)-directed antibody-drug conjugate carrying a proprietary topoisomerase I (TopoIx) payload, have been accepted for an oral presentation at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026). The meeting will be held November 18-20, 2026, at the CCIB in Barcelona, Spain.
The presentation, titled "Phase 1 study of BHV-1530, a first-in-class FGFR3 (搜索) ADC in Advanced Tumors," is abstract number 2 and is scheduled in Plenary Session 3 on Nov. 19, 2026, at 10:00 a.m. It will provide an update from the ongoing BHV1530-101 study (NCT06874335).
Trial Design and Patient Population
BHV1530-101 is a Phase 1, first-in-human, open-label, multicenter study with dose-escalation, dose-expansion and dose-confirmation stages. It evaluates BHV-1530 as monotherapy and in combination with cemiplimab in adults with advanced or metastatic solid tumors.
The dose-escalation portion is enrolling unselected patients with advanced urothelial cancer (搜索), head and neck squamous cell carcinoma (搜索), and non-small cell lung cancer (搜索) who have failed standard-of-care therapy, along with patients whose tumors harbor FGFR3 (搜索) genomic alterations.
Early Activity and Safety Profile
Biohaven reported that early clinical activity has been observed, including confirmed partial responses in heavily pretreated patients, as previously disclosed. The data have shown a favorable and differentiated safety profile, with no dose-limiting toxicities and no FGFR inhibitor-class toxicities such as hyperphosphatemia, nail disorders, stomatitis or retinopathy. Those class effects commonly constrain the dosing and treatment duration of approved FGFR tyrosine kinase inhibitors, according to the company.
Targeting FGFR3 Beyond Pathway Inhibition
BHV-1530 is described as a first-in-class potential ADC directed against FGFR3 (搜索), a validated but underexploited target in urothelial cancer (搜索) and other FGFR3-driven cancers. Unlike approved FGFR tyrosine kinase inhibitors, which are restricted to genomically selected patients and limited by class-related toxicities, BHV-1530 is designed to target FGFR3 without requiring pathway inhibition. That design gives it the potential to address both FGFR3-altered tumors and tumors with wild-type FGFR3 overexpression, a population not addressed by approved FGFR tyrosine kinase inhibitors.
Cemiplimab Combination Enters Enrollment
Biohaven has entered a clinical supply agreement with Regeneron Pharmaceuticals, Inc. to evaluate BHV-1530 with cemiplimab (Libtayo) in patients with solid tumors. Enrollment into the combination cohort has begun.
The rationale rests on previously disclosed emerging monotherapy clinical data and preclinical data showing synergistic activity between BHV-1530 and anti-PD-1 therapy. Biohaven said the TopoIx payload has been demonstrated to generate immunogenic cell death and stimulate an antitumor immune response, providing a mechanistic basis for combining the ADC with checkpoint inhibition.
The agreement extends an existing clinical supply arrangement between the two companies for BHV-1510, a next-generation TROP2-directed ADC, across Biohaven's oncology pipeline.
Biohaven is a clinical-stage biopharmaceutical company whose programs span immunology, neuroscience and oncology, including Kv7 ion channel modulation for epilepsy, MoDE and TRAP extracellular protein degradation for immunological diseases, and myostatin inhibition for neuromuscular and metabolic diseases including obesity.